242
Views
5
CrossRef citations to date
0
Altmetric
INVITED EDITORIALS

Estrogen as a new option for prevention and treatment of breast cancer – does this need a ‘time gap’?

&
Pages 444-447 | Received 02 Apr 2015, Accepted 14 Apr 2015, Published online: 11 May 2015

References

  • Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 2015;22: R1–31
  • Haddow A, Watkinson JM, Paterson E, Koller PC. Influence of synthetic oestrogens on advanced malignant disease. BMJ 1944;2:393–8
  • Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA. Estradiol-induced regression in T47D:A18/PKCa tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res 2009;7:498–510
  • Fan P, Griffith OL, Agboke FA, et al. c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res 2013;73:4510–20
  • Sweeney EE, Fan P, Jordan VC. Molecular modulation of estrogen induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the Women’s Health Initiative study. Cancer Res 2014;74:7060–8
  • LaCroix AZ, Chlebowski RT, Manson JE, et al.; WHI investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. JAMA 2011;305:1305–14
  • Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
  • Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3–7
  • Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen–progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138–43
  • Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345:e6409
  • Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:774–80
  • Service RF. New role of estrogen in cancer. Science 1998; 279:1631–7
  • Mueck AO, Seeger H. Breast cancer: are estrogen metabolites carcinogenic? Climacteric 2007;10(Suppl 2):62–5
  • Ruan X, Mueck AO. Impact of smoking on estrogenic efficacy. Climacteric 2015;18:38–46
  • Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and malignant disease. Maturitas 2002;43:1–10
  • Mueck AO, Seeger H. 2-Methoxyestradiol – biology and mechanism of action. Steroids 2010;75:625–31
  • Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052–60
  • Mueck AO, Ruan X, Seeger H, Fehm T, Neubauer H. Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol 2014;142:62–7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.